Efficacy and safety of doxazosin in the treatment of mild to moderate essential hypertension

This was an open, non-comparative study on the efficacy and tolerability of doxazosin in the treatment of mild to moderate essential hypertension. 40 patients of both sexes were treated with doxazosin once daily for 10 weeks. The mean reduction in systolic and diastolic blood pressure from baseline to the end of the study was 20 mmHg and 22 mmHg respectively. These reductions were found to be statistically significant [p<0.05]. The mean reduction in the heart rate from baseline to the end of the study was 5 beats/min. These reductions were thought statistically significant [p<0.05] had no clinical relevance. At baseline the mean values for total cholesterol was 175mg/dl, for HDL 36.1mg/dl, for HDL 111.8mg/dl, and for triglycerides was 153.8mg/dl. At the end of the study the mean values for total cholesterol was 166.0mg/dl, for HDL was 34.2mg/dl, for LDL was 99.6mg/dl, and for triglycerides was 138.7mg/dl. The effect of doxazosin on the serum lipids of the patients was noted and some reduction was found in the total cholesterol, HDL, LDL and triglycerides. However, these reduction were not statistically significant. None of the patients experienced any adverse effects of doxazosin and no patient was withdrawn from the study due to any adverse events. These findings indicate that doxazosin is an effective and well tolerated antihypertensive agent for mild to moderate essential hypertension